VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ARDXArdelyx, Inc.
$6.05$1.5B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

ARDX logoArdelyx, Inc.(ARDX)Earnings, Financials & Key Ratios

ARDX•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCommercial Specialty Pharma
AboutArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more
  • Revenue$407M+22.1%
  • EBITDA-$38M-46.5%
  • Net Income-$62M-57.4%
  • EPS (Diluted)-0.26-52.9%
  • Gross Margin89.54%+5.5%
  • EBITDA Margin-9.31%-20.0%
  • Operating Margin-10.06%-20.1%
  • Net Margin-15.12%-28.9%
  • ROE-36.21%-57.3%

ARDX Key Insights

Ardelyx, Inc. (ARDX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 121.9%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ARDX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ARDX Price & Volume

Ardelyx, Inc. (ARDX) stock price & volume — 10-year historical chart

Loading chart...

ARDX Growth Metrics

Ardelyx, Inc. (ARDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years32.72%
5 Years121.9%
3 Years98.4%
TTM18.24%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-7.99%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-4.77%

Return on Capital

10 Years-48.82%
5 Years-45.14%
3 Years-17.97%
Last Year-10.63%

ARDX Recent Earnings

Ardelyx, Inc. (ARDX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 30, 2026
Metric
Actual
Est
EPS
$0.15-15.4%
$0.13
Rev
$94M+1.8%
$93M
Q1 2026
Feb 19, 2026
Metric
Actual
Est
EPS
$0.02+0.0%
$0.02
Rev
$125M+6.1%
$118M
Q4 2025
Oct 30, 2025
Metric
Actual
Est
EPS
$0.00+93.3%
$0.06
Rev
$110M-7.3%
$119M
Q3 2025
Aug 4, 2025
Metric
Actual
Est
EPS
$0.08+38.5%
$0.13
Rev
$98M+3.2%
$95M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$0.15vs $0.13-15.4%
$94Mvs $93M+1.8%
Q1 2026Feb 19, 2026
$0.02vs $0.02+0.0%
$125Mvs $118M+6.1%
Q4 2025Oct 30, 2025
$0.00vs $0.06+93.3%
$110Mvs $119M-7.3%
Q3 2025Aug 4, 2025
$0.08vs $0.13+38.5%
$98Mvs $95M+3.2%
Based on last 12 quarters of dataView full earnings history →

ARDX Peer Comparison

Ardelyx, Inc. (ARDX) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
CYCN logoCYCNCyclerion Therapeutics, Inc.Direct Competitor13.86M3.20-2.943.7%-264.73%-62.1%
CHRS logoCHRSCoherus Oncology, Inc.Direct Competitor181.17M1.48-1.02-84.2%-323.49%-174.71%0.66
PRAX logoPRAXPraxis Precision Medicines, Inc.Direct Competitor8.15B282.31-20.94-100%-43.02%0.00
INVA logoINVAInnoviva, Inc.Direct Competitor1.66B22.496.8218.52%118.91%47.59%0.23
SUPN logoSUPNSupernus Pharmaceuticals, Inc.Direct Competitor2.56B44.38-65.268.63%-3.74%-2.73%0.04
ASRT logoASRTAssertio Holdings, Inc.Direct Competitor151.86M23.50-4.96-5%-34.94%-38.72%0.42
VKTX logoVKTXViking Therapeutics, Inc.Product Competitor3.52B30.38-9.52-71.31%0.00
AGIO logoAGIOAgios Pharmaceuticals, Inc.Product Competitor2.03B34.16-4.8048.03%-6.4%-34.11%0.05

Compare ARDX vs Peers

Ardelyx, Inc. (ARDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CYCN

Most directly comparable listed peer for ARDX.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ARDX against a more recognizable public peer.

Peer Set

Compare Top 5

vs CYCN, CHRS, PRAX, INVA

ARDX Income Statement

Ardelyx, Inc. (ARDX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
42M2.61M5.28M7.57M10.1M52.16M124.46M333.62M407.32M427.68M
Revenue Growth %
74.81%-93.79%102.57%43.36%33.36%416.57%138.61%168.06%22.09%18.24%
Cost of Goods Sold
8.4M466K600K145K1M4.12M17.8M50.56M42.6M34.5M
COGS % of Revenue
20%17.88%11.36%1.92%9.9%7.89%14.3%15.15%10.46%-
Gross Profit
33.6M▲ 0%
2.14M▼ 93.6%
4.68M▲ 118.6%
7.43M▲ 58.6%
9.1M▲ 22.5%
48.04M▲ 428.1%
106.66M▲ 122.0%
283.06M▲ 165.4%
364.72M▲ 28.9%
393.18M▲ 0%
Gross Margin %
80%82.13%88.64%98.08%90.1%92.11%85.7%84.85%89.54%91.93%
Gross Profit Growth %
47.82%-93.63%118.64%58.64%22.5%428.1%122.02%165.38%28.85%-
Operating Expenses
98.72M93.09M95.94M98.21M163.44M111.8M169.94M311.01M405.7M430.6M
OpEx % of Revenue
235.04%3570.69%1816.78%1297.13%1618.73%214.35%136.54%93.22%99.6%-
Selling, General & Admin
23.23M23.71M24.27M33.15M72.3M76.6M134.4M258.69M337.23M356.28M
SG&A % of Revenue
55.31%909.67%459.52%437.89%716.08%146.86%107.99%77.54%82.79%-
Research & Development
75.48M69.37M71.68M65.05M91.14M35.2M35.54M52.32M68.47M74.32M
R&D % of Revenue
179.72%2661.03%1357.26%859.24%902.64%67.49%28.55%15.68%16.81%-
Other Operating Expenses
0000000000
Operating Income
-65.11M▲ 0%
-90.95M▼ 39.7%
-91.26M▼ 0.3%
-90.78M▲ 0.5%
-154.35M▼ 70.0%
-63.76M▲ 58.7%
-63.28M▲ 0.8%
-27.95M▲ 55.8%
-40.98M▼ 46.6%
-37.42M▲ 0%
Operating Margin %
-155.04%-3488.57%-1728.14%-1199.05%-1528.63%-122.24%-50.84%-8.38%-10.06%-8.75%
Operating Income Growth %
42.32%-39.67%-0.35%0.53%-70.02%58.69%0.76%55.83%-46.61%-
EBITDA
-62.48M-88.27M-86.92M-86.81M-151.54M-62.62M-61.98M-25.89M-37.92M-34.96M
EBITDA Margin %
-148.75%-3385.85%-1645.96%-1146.6%-1500.83%-120.05%-49.8%-7.76%-9.31%-8.18%
EBITDA Growth %
44.02%-41.28%1.52%0.13%-74.57%58.68%1.01%58.24%-46.48%6.49%
D&A (Non-Cash Add-back)
2.64M2.68M4.34M3.97M2.81M1.14M1.29M2.06M3.06M2.46M
EBIT
-63.16M-87.76M-88.91M-89.21M-153.66M-62.13M-56.65M-18.78M-40.98M-4.63M
Net Interest Income
0-3.53M-5.73M-5.1M-4.5M-5.07M-8.87M-20.09M-28.4M-22.14M
Interest Income
0000000000
Interest Expense
03.53M5.73M5.1M4.5M5.07M8.87M20.09M28.4M16.54M
Other Income/Expense
1.96M-347K-3.37M-3.53M-3.81M-3.44M-2.24M-10.92M-19.65M-20.52M
Pretax Income
-63.16M▲ 0%
-91.29M▼ 44.5%
-94.64M▼ 3.7%
-94.31M▲ 0.3%
-158.16M▼ 67.7%
-67.2M▲ 57.5%
-65.52M▲ 2.5%
-38.87M▲ 40.7%
-60.63M▼ 56.0%
-57.94M▲ 0%
Pretax Margin %
-150.38%-3501.88%-1792.03%-1245.69%-1566.42%-128.84%-52.65%-11.65%-14.89%-13.55%
Income Tax
1.18M4K303K2K4K8K547K266K969K118K
Effective Tax Rate %
-1.87%-0%-0.32%-0%-0%-0.01%-0.83%-0.68%-1.6%-0.2%
Net Income
-64.34M▲ 0%
-91.3M▼ 41.9%
-94.94M▼ 4.0%
-94.31M▲ 0.7%
-158.16M▼ 67.7%
-67.21M▲ 57.5%
-66.07M▲ 1.7%
-39.14M▲ 40.8%
-61.6M▼ 57.4%
-58.06M▲ 0%
Net Margin %
-153.19%-3502.03%-1797.77%-1245.71%-1566.46%-128.85%-53.08%-11.73%-15.12%-13.58%
Net Income Growth %
42.75%-41.9%-3.99%0.66%-67.7%57.51%1.7%40.76%-57.4%-7.99%
Net Income (Continuing)
-64.34M-91.3M-94.94M-94.31M-158.16M-67.21M-66.07M-39.14M-61.6M-58.06M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-1.36▲ 0%
-1.62▼ 19.1%
-1.47▲ 9.3%
-1.05▲ 28.6%
-1.52▼ 44.8%
-0.42▲ 72.4%
-0.30▲ 28.6%
-0.17▲ 43.3%
-0.26▼ 52.9%
-0.24▲ 0%
EPS Growth %
51.43%-19.12%9.26%28.57%-44.76%72.37%28.57%43.33%-52.94%-4.77%
EPS (Basic)
-1.36-1.62-1.47-1.05-1.52-0.42-0.30-0.17-0.26-
Diluted Shares Outstanding
47.44M56.22M64.48M89.58M104.21M158.69M219.33M235.23M241.03M245.86M
Basic Shares Outstanding
47.44M56.22M64.48M89.58M104.21M158.69M219.33M235.23M241.03M245.86M
Dividend Payout Ratio
----------

ARDX Balance Sheet

Ardelyx, Inc. (ARDX) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
149.87M177.72M252.38M195.24M133.65M153.6M246.11M356.45M382.32M381.87M
Cash & Short-Term Investments
133.98M168.09M247.51M186.48M116.69M123.91M184.3M250.1M264.69M238.07M
Cash Only
75.38M78.77M181.13M91.03M72.43M96.14M21.47M64.93M68M31.21M
Short-Term Investments
58.59M89.32M66.38M95.45M44.26M27.77M162.83M185.17M196.69M206.87M
Accounts Receivable
10.8M5.08M750K0502K7.73M22.03M57.7M71.85M82.84M
Days Sales Outstanding
93.82711.9451.84-18.1554.1264.6163.1364.3862.7
Inventory
000003.28M12.45M21.17M17.73M22.75M
Days Inventory Outstanding
-----290.97255.33152.86151.97232.55
Other Current Assets
000015.11M8.41M11.1M28.05M38.21M
Total Non-Current Assets
8.03M5.61M7.41M6.32M16.26M36.46M51.47M79.3M119.29M122.64M
Property, Plant & Equipment
8.03M5.61M7.41M4.21M15.11M10.52M6.6M3.88M6.98M6.43M
Fixed Asset Turnover
5.23x0.46x0.71x1.80x0.67x4.96x18.86x86.09x58.36x61.57x
Goodwill
0000000000
Intangible Assets
0000000000
Long-Term Investments
0002.11M000000
Other Non-Current Assets
00001.15M25.95M44.87M75.43M112.31M116.2M
Total Assets
157.9M▲ 0%
183.33M▲ 16.1%
259.78M▲ 41.7%
201.56M▼ 22.4%
149.91M▼ 25.6%
190.07M▲ 26.8%
297.58M▲ 56.6%
435.75M▲ 46.4%
501.6M▲ 15.1%
504.51M▲ 0%
Asset Turnover
0.27x0.01x0.02x0.04x0.07x0.27x0.42x0.77x0.81x0.87x
Asset Growth %
-25.91%16.1%41.7%-22.41%-25.62%26.78%56.57%46.43%15.11%106.43%
Total Current Liabilities
17.87M17.73M22.22M28.42M52.82M65.6M50.39M77.83M88.61M109.57M
Accounts Payable
3.93M1.15M2.19M5.63M4.28M10.86M11.14M16M19.23M28.2M
Days Payables Outstanding
170.9899.181.33K14.16K1.56K962.72228.46115.52164.82231.43
Short-Term Debt
003.79M6.28M32.26M26.71M001.48M1.51M
Deferred Revenue (Current)
01M4.54M4.18M04.21M7.18M10.69M1.21M17.32M
Other Current Liabilities
10.71M12.86M4.64M5.22M1.24M10.09M15.04M49.58M66.69M76.61M
Current Ratio
8.39x10.02x11.36x6.87x2.53x2.34x4.88x4.58x4.31x3.49x
Quick Ratio
8.39x10.02x11.36x6.87x2.53x2.29x4.64x4.31x4.11x3.28x
Cash Conversion Cycle
------617.6491.48100.4851.5363.81
Total Non-Current Liabilities
720K49.79M50.91M47.03M14.47M26.13M80.37M184.63M246.05M246.32M
Long-Term Debt
049.21M48.83M46.62M0049.82M150.85M206.47M206.75M
Capital Lease Obligations
002.08M413K9.75M5.86M1.73M1.02M3.64M11.69M
Deferred Tax Liabilities
0000000001.2M
Other Non-Current Liabilities
720K582K004.73M11.25M20.18M25.53M-3.64M39.56M
Total Liabilities
18.59M67.52M73.13M75.45M67.3M91.74M130.76M262.46M334.65M355.88M
Total Debt
049.21M57.31M55.44M45.5M36.46M55.98M153.44M211.59M208.26M
Net Debt
-75.38M-29.56M-123.83M-35.6M-26.92M-59.68M34.51M88.51M143.6M177.06M
Debt / Equity
-0.42x0.31x0.44x0.55x0.37x0.34x0.89x1.27x1.40x
Debt / EBITDA
----------5.96x
Net Debt / EBITDA
----------5.06x
Interest Coverage
--24.83x-15.53x-17.50x-34.13x-12.25x-6.38x-0.93x-1.44x-0.28x
Total Equity
139.31M▲ 0%
115.81M▼ 16.9%
186.66M▲ 61.2%
126.11M▼ 32.4%
82.62M▼ 34.5%
98.33M▲ 19.0%
166.82M▲ 69.7%
173.29M▲ 3.9%
166.95M▼ 3.7%
148.62M▲ 0%
Equity Growth %
-27.87%-16.87%61.17%-32.44%-34.49%19.02%69.65%3.88%-3.66%-9.25%
Book Value per Share
2.942.062.891.410.790.620.760.740.690.60
Total Shareholders' Equity
139.31M115.81M186.66M126.11M82.62M98.33M166.82M173.29M166.95M148.62M
Common Stock
5K6K9K9K13K20K23K24K24K25K
Retained Earnings
-278.21M-365.51M-460.45M-554.76M-712.93M-780.14M-846.2M-885.34M-946.94M-984.54M
Treasury Stock
0000000000
Accumulated OCI
-47K-38K20K-4K-6K-54K224K57K198K-124K
Minority Interest
0000000000

ARDX Cash Flow Statement

Ardelyx, Inc. (ARDX) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-65.19M-70.27M-76.48M-81.44M-152.55M-70.04M-89.72M-44.81M-42.48M-36.26M
Operating CF Margin %
-155.21%-2695.59%-1448.29%-1075.62%-1510.85%-134.29%-72.09%-13.43%-10.43%-
Operating CF Growth %
29.55%-7.8%-8.84%-6.47%-87.33%54.08%-28.09%50.06%5.19%71.95%
Net Income
-64.34M-91.3M-94.94M-94.31M-158.16M-67.21M-66.07M-39.14M-61.6M-58.06M
Depreciation & Amortization
2.64M2.68M2.5M1.82M1.44M1.14M1.29M2.06M3.06M3.37M
Stock-Based Compensation
9.59M9.23M9.94M10.58M12.04M10.75M13.53M37.38M48.96M38.59M
Deferred Taxes
11K-1.02M-262K315K-190K00000
Other Non-Cash Items
567K792K3.3M3.37M4.25M4.84M4.91M4.05M-1.55M8.06M
Working Capital Changes
-13.66M9.35M2.98M-3.21M-11.92M-19.57M-43.39M-49.17M-31.35M-28.23M
Change in Receivables
-10.8M10.71M85K750K-502K-7.23M-14.3M-35.67M-14.14M-36.37M
Change in Inventory
-1.9M1.88M-3.41M-750K-10.37M-28.35M-21.14M-41.7M-31.92M-22.15M
Change in Payables
-1.03M-2.73M39K3.44M-1.35M6.58M279K4.86M3.23M14.47M
Cash from Investing
65.29M-29.89M23.37M-31.44M50.95M18.41M-131.25M-18.32M-8.96M-21.8M
Capital Expenditures
-2.35M-311K-325K-324K-1.87M-55K-344K-1.01M-1.49M-1.24M
CapEx % of Revenue
5.61%11.93%6.15%4.28%18.49%0.11%0.28%0.3%0.37%0.29%
Acquisitions
00-23.7M31.44M-52.81M00000
Investments
----------
Other Investing
67.64M-29.58M23.7M-31.44M52.81M1.8M0000
Cash from Financing
685K103.55M155.48M22.78M83M75.34M146.29M106.59M54.51M58.47M
Debt Issued (Net)
049.29M0-125K-19.44M-6.07M22.39M99.45M48.67M48.67M
Equity Issued (Net)
053.77M154.9M21.05M101.15M71.63M119.24M8.14M5.84M9.8M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
685K491K574K1.85M1.3M9.78M4.67M-1M00
Net Change in Cash
785K▲ 0%
3.38M▲ 331.2%
102.36M▲ 2924.1%
-90.1M▼ 188.0%
-18.6M▲ 79.4%
23.71M▲ 227.5%
-74.67M▼ 414.9%
43.46M▲ 158.2%
3.07M▼ 92.9%
401K▲ 0%
Free Cash Flow
-67.55M▲ 0%
-70.58M▼ 4.5%
-76.81M▼ 8.8%
-81.76M▼ 6.4%
-154.42M▼ 88.9%
-70.1M▲ 54.6%
-90.06M▼ 28.5%
-45.82M▲ 49.1%
-43.98M▲ 4.0%
-37.5M▲ 0%
FCF Margin %
-160.82%-2707.52%-1454.44%-1079.9%-1529.35%-134.4%-72.36%-13.73%-10.8%-8.77%
FCF Growth %
30.65%-4.5%-8.82%-6.44%-88.87%54.6%-28.48%49.12%4.03%23.05%
FCF per Share
-1.42-1.26-1.19-0.91-1.48-0.44-0.41-0.19-0.18-0.15
FCF Conversion (FCF/Net Income)
1.01x0.77x0.81x0.86x0.96x1.04x1.36x1.14x0.69x0.65x
Interest Paid
004.92M4.2M3.47M2.9M4.24M11.41M08.4M
Taxes Paid
3K4K2K1K4K6K51K266K0489K

ARDX Key Ratios

Ardelyx, Inc. (ARDX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-38.7%-71.57%-62.78%-60.31%-151.55%-74.28%-49.83%-23.01%-36.21%-38.11%
Return on Invested Capital (ROIC)
-53.52%-90.84%-91.83%-88.8%-158.35%-101.37%-39.55%-9.05%-10.74%-9.27%
Gross Margin
80%82.13%88.64%98.08%90.1%92.11%85.7%84.85%89.54%91.93%
Net Margin
-153.19%-3502.03%-1797.77%-1245.71%-1566.46%-128.85%-53.08%-11.73%-15.12%-13.58%
Debt / Equity
-0.42x0.31x0.44x0.55x0.37x0.34x0.89x1.27x1.40x
Interest Coverage
--24.83x-15.53x-17.50x-34.13x-12.25x-6.38x-0.93x-1.44x-0.28x
FCF Conversion
1.01x0.77x0.81x0.86x0.96x1.04x1.36x1.14x0.69x0.65x
Revenue Growth
74.81%-93.79%102.57%43.36%33.36%416.57%138.61%168.06%22.09%18.24%
Related:ARDX Dividend History·ARDX Revenue History·ARDX Price History·ARDX P/E History·ARDX Financial Ratios·ARDX Institutional Holders

ARDX SEC Filings & Documents

Ardelyx, Inc. (ARDX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Feb 19, 2026·SEC

Material company update

Jan 8, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 19, 2026·SEC

FY 2025

Feb 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 30, 2025·SEC

FY 2025

Aug 4, 2025·SEC

ARDX Frequently Asked Questions

Ardelyx, Inc. (ARDX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Ardelyx, Inc. (ARDX) reported $427.7M in revenue for fiscal year 2025. This represents a 7805% increase from $5.4M in 2012.

Ardelyx, Inc. (ARDX) grew revenue by 22.1% over the past year. This is strong growth.

Ardelyx, Inc. (ARDX) reported a net loss of $58.1M for fiscal year 2025.

Dividend & Returns

Ardelyx, Inc. (ARDX) has a return on equity (ROE) of -36.2%. Negative ROE indicates the company is unprofitable.

Ardelyx, Inc. (ARDX) had negative free cash flow of $37.5M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ARDX back in 2012?

Total return calculator · dividends reinvested · 14+ years of data

See returns →

How much would $100/month in ARDX be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →